Timeline of incretin therapeutics: difference between revisions

Diff·revision 9 → 10·18:22, 8 Dec 2024

Difference between revision 9 and revision 10 of Timeline of incretin therapeutics. 12 lines changed; the page grew by 461 bytes.

Revision 9 — 00:25, 14 Nov 2024 DulaglutideDug (talk) expand §Physiology 2,352 bytes ±0	Revision 10 — 18:22, 8 Dec 2024 Compounding_Cate (talk) add the receptor targets to the lead sentence 2,813 bytes +461
1	{{Infobox list	1	{{Infobox list
2	\| name = Timeline of incretin therapeutics	2	\| name = Timeline of incretin therapeutics
+		3	\| subtitle = Reference material
3	\| Span = 1900s to the present	4	\| Span = 1900s to the present
4	\| Arrangement = Chronological	5	\| Arrangement = Chronological
⋮		⋮
24		25
25	Identification of DPP-4 as the inactivating enzyme defined the engineering problem every subsequent agonist solves. See [[GLP-1 receptor agonist]].{{r\|drucker2018}}	26	Identification of DPP-4 as the inactivating enzyme defined the engineering problem every subsequent agonist solves. See [[GLP-1 receptor agonist]].{{r\|drucker2018}}
+		27
+		28	== First-generation drugs ==
+		29	\| Year \| Event \|
+		30	\|---\|---\|
+		31	\| 1990s \| Exendin-4 identified in Gila monster venom \|
+		32	\| 2005 \| [[Exenatide]] approved — first GLP-1 receptor agonist \|
+		33	\| 2006 \| First DPP-4 inhibitor approved \|
+		34	\| 2009 \| [[Liraglutide]] approved for type 2 diabetes \|
+		35	\| 2014 \| Liraglutide approved for weight management \|
+		36	\| 2014 \| [[Dulaglutide]] approved \|
+		37	\| 2016 \| [[LEADER trial]] reports cardiovascular benefit \|
26		38
27	== References ==	39	== References ==